Repairon is focused on advancing heart repair through the development of induced pluripotent stem cell (iPSC)-based tissues, specifically engineered heart muscle (EHM) patches. These patches are designed to treat patients suffering from advanced heart failure by remuscularizing the failing heart, thereby providing both structural and functional support. The company’s lead product, EHM, is produced from a well-characterized iPSC line derived from hematopoietic stem cells. This innovative approach allows for the creation of self-contracting heart tissues that can be surgically implanted to restore heart function, addressing a significant unmet medical need in a patient population that experiences high mortality rates and diminished quality of life.

Repairon’s technology leverages a two-step process to generate EHM. Initially, cardiomyocytes and stromal cells are derived from the iPSC line, which are then formulated in a collagen hydrogel to facilitate their self-organization into functional heart muscle tissue. This engineered heart muscle can be produced in various forms, such as patches for localized repair or pouches for supporting enlarged hearts. The company is also developing second-generation products that aim to reduce the need for immune suppression and enhance the efficacy of the engineered tissues by co-delivering protective factors. Overall, Repairon’s innovative technologies represent a promising advancement in regenerative therapies for heart disease, with the potential to significantly improve patient outcomes.

Germany

Repairon's mission is the development, the manufacturing and the commercialization of induced pluripotent stem cell (iPSC) based tissues for organ repair. Our lead product are contractile heart tissue patches – Engineered Human Myocardium (EHM) – for the treatment of patients with advanced heart failure.

Repairon

Company Details